10/28/2025
                                            CLINICAL TRIAL NEWS:
New Myeloma Drug Combo Gives Fresh Hope for Patients: FDA Approves Blenrep + Velcade + Dexamethasone After Prior Treatments
If your multiple myeloma has come back or stopped responding after at least two different treatments, there’s a new option: a combination of Blenrep (belantamab mafodotin), Velcade (bortezomib), and dexamethasone. 
This newly approved drug combo was tested in a large clinical trial with real patients. Compared to one of the most common options, it cut the risk of death in half and more than tripled the time before the cancer grew again—often giving many extra months and even years of life.
WHY IT MATTERS?
This approval is for people running out of choices, showing research continues to create new lifelines.
Clinical trials like DREAMM-7—thanks to patients who volunteered—make new treatments like this available.
While side effects are still present (especially eye issues), doctors see this as a meaningful advance, with the treatment also available in local community centers for easier access.
BOTTOM LINE:
Progress like this only happens because myeloma fighters step up to join trials. Every advance offers real hope for more time and better options at every stage of the journey.
INTERESTED IN LEARNING MORE? Links in Comment Below                                        
Send a message to learn more
 
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                                                                                     
                                         
   
   
   
   
     
   
   
  